Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
12 oct. 2021 16h35 HE
|
Cellectis Inc.
NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using...
Monthly information on share capital and company voting rights
10 sept. 2021 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT
29 juil. 2021 16h34 HE
|
Cellectis Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology...
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET
29 juil. 2021 16h34 HE
|
Cellectis Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ : CLLS – EURONEXT GROWTH : ALCLS) (la « Société »), une société d’édition du génome spécialisée dans les essais en immuno-oncologie...
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
14 juin 2021 16h30 HE
|
Cellectis Inc.
• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates...
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021
02 juin 2021 02h30 HE
|
Cellectis Inc.
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France. ...
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
11 mai 2021 16h30 HE
|
Cellectis Inc.
PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop...
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
06 mai 2021 16h30 HE
|
Cellectis Inc.
Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical...
Cellectis Completes Sale of $47 million through its ATM program
09 avr. 2021 02h30 HE
|
Cellectis Inc.
NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary...
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
29 mars 2021 16h50 HE
|
Cellectis Inc.
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary...